Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time.

Gallwitz B, Vaag A, Falahati A, Madsbad S

International journal of clinical practice17 Nov 2009Cited by 49 (Europe PMC)

PMID19925617DOI10.1111/j.1742-1241.2009.02265.xPepBankPUB-19925617

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, liraglutide added to oral antidiabetic drugs significantly reduced HbA1c within 8 weeks, and the reduction was maintained to week 26.
In plain wordsIn adults with type 2 diabetes, adding liraglutide to oral drugs lowered HbA1c within 8 weeks and kept it down to week 26.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction onset
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg and 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Significant reductions in HbA(1c) were observed within 8 weeks of treatment with liraglutide plus OADs (p < 0.0001) and maintained until week 26.
3 context sentences(design, population, supporting numbers)
Summary · context
This analysis included patients from three phase 3, 26-week, randomised, double-blind, parallel-group trials.
Summary · context
Patients were then randomised to receive liraglutide (0.6, 1.2 or 1.8 mg once-daily), active comparator and/or placebo.
Summary · context
For this analysis, only the 1.2 mg and 1.8 mg liraglutide doses were included.
Report a problemFND-1992561701
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, liraglutide added to oral antidiabetic drugs significantly reduced fasting plasma glucose within 2 weeks, sustained over 26 weeks.
In plain wordsIn adults with type 2 diabetes, adding liraglutide to oral drugs lowered fasting blood sugar within 2 weeks, and it stayed lower.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose reduction onset
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg and 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Furthermore, liraglutide plus OADs led to significant reductions in FPG within 2 weeks (p < 0.0001) and sustained over 26 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
This analysis included patients from three phase 3, 26-week, randomised, double-blind, parallel-group trials.
Summary · context
Patients were then randomised to receive liraglutide (0.6, 1.2 or 1.8 mg once-daily), active comparator and/or placebo.
Summary · context
For this analysis, only the 1.2 mg and 1.8 mg liraglutide doses were included.
Report a problemFND-1992561702
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, adding liraglutide to metformin, with or without rosiglitazone, reduced body weight within 8 weeks, and the reduction was maintained.
In plain wordsIn adults with type 2 diabetes, adding liraglutide to metformin, with or without rosiglitazone, lowered weight within 8 weeks.
Peptide
Liraglutide
Outcome
DecreaseBody weight with metformin or metformin plus rosiglitazone
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg and 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Adding liraglutide to metformin or metformin plus rosiglitazone also led to early reductions and maintained reductions in body weight (within 8 weeks, p < 0.0001)
3 context sentences(design, population, supporting numbers)
Summary · context
This analysis included patients from three phase 3, 26-week, randomised, double-blind, parallel-group trials.
Summary · context
Patients were then randomised to receive liraglutide (0.6, 1.2 or 1.8 mg once-daily), active comparator and/or placebo.
Summary · context
For this analysis, only the 1.2 mg and 1.8 mg liraglutide doses were included.
Report a problemFND-1992561703
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, liraglutide added to glimepiride was weight neutral.
In plain wordsIn adults with type 2 diabetes, liraglutide added to glimepiride did not change weight.
Peptide
Liraglutide
Outcome
No significant changeBody weight with glimepiride
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg and 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
however, liraglutide treatment plus glimepiride was weight neutral.
3 context sentences(design, population, supporting numbers)
Summary · context
This analysis included patients from three phase 3, 26-week, randomised, double-blind, parallel-group trials.
Summary · context
Patients were then randomised to receive liraglutide (0.6, 1.2 or 1.8 mg once-daily), active comparator and/or placebo.
Summary · context
For this analysis, only the 1.2 mg and 1.8 mg liraglutide doses were included.
Report a problemFND-1992561704
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, liraglutide added to oral antidiabetic drugs rapidly reduced systolic blood pressure within 2 weeks, maintained for 26 weeks.
In plain wordsIn adults with type 2 diabetes, adding liraglutide to oral drugs lowered systolic blood pressure within 2 weeks, and it stayed lower.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure reduction onset
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.2 mg and 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Rapid reductions in SBP were observed for liraglutide plus OADs (within 2 weeks, p < 0.05-0.001) and maintained for 26 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
This analysis included patients from three phase 3, 26-week, randomised, double-blind, parallel-group trials.
Summary · context
Patients were then randomised to receive liraglutide (0.6, 1.2 or 1.8 mg once-daily), active comparator and/or placebo.
Summary · context
For this analysis, only the 1.2 mg and 1.8 mg liraglutide doses were included.
Report a problemFND-1992561705
06HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, some patients on liraglutide experienced nausea, which diminished within 2 weeks in the majority.
In plain wordsIn adults with type 2 diabetes, some patients on liraglutide felt nausea, which faded within 2 weeks for most.
Peptide
Liraglutide
Outcome
Not applicableNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 mg and 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Some patients experienced nausea, which for the majority it diminished within 2 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
This analysis included patients from three phase 3, 26-week, randomised, double-blind, parallel-group trials.
Summary · context
Patients were then randomised to receive liraglutide (0.6, 1.2 or 1.8 mg once-daily), active comparator and/or placebo.
Summary · context
For this analysis, only the 1.2 mg and 1.8 mg liraglutide doses were included.
Report a problemFND-1992561706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.